Rhu-pGSN for Severe Covid-19 Pneumonia
NCT04358406
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
Sars-CoV2
Interventions
DRUG:
Recombinant human plasma gelsolin (Rhu-pGSN)
OTHER:
Placebo
Sponsor
BioAegis Therapeutics Inc.